Vermillion’s Aspira Labs Secures Expanded Medi-Cal Coverage for OVA1March 7, 2017
March 7, 2017
GenomeWeb – Staff Reporter
Vermillion said yesterday that its Aspira Labs subsidiary has won out-of-state provider status with Medi-Cal, California’s Medicaid program, for its OVA1 ovarian cancer test.
The status gives the company access to more than 12 million Medi-Cal beneficiaries, representing roughly one-third of the covered lives in California, Vermillion said.
“This new status is an expansion to our prior Medi-Cal coverage and is key to reaching the entire Medicaid base, as well as expanding OVA1 access in the state with the largest US population,” Valerie Palmieri, president and CEO of Vermillion, said in a statement.News. Bookmark the permalink. ← LabCorp to Acquire Lab Diagnostics Player PAML CMS Will Give Labs More Time to Report PAMA-Required Payor Data →